Paraproteinemias
A group of related diseases characterized by an unbalanced or disproportionate proliferation of immunoglobulin-producing cells, usually from a single clone. These cells frequently secrete a structurally homogeneous immunoglobulin (M-component) and/or an abnormal immunoglobulin.
Subtype terms (8)
More specific conditions that are subtypes of Paraproteinemias in the MeSH hierarchy.
- Cryoglobulinemia
9 drugs approved
- Heavy Chain Disease
- Immunoglobulin Light-chain Amyloidosis
59 drugs (43 approved, 16 experimental)
- Monoclonal Gammopathy of Undetermined Significance
27 drugs (23 approved, 4 experimental)
- Multiple Myeloma
992 drugs (335 approved, 657 experimental)
- POEMS Syndrome
12 drugs (7 approved, 5 experimental)
- Smoldering Multiple Myeloma
39 drugs (29 approved, 10 experimental)
- Waldenstrom Macroglobulinemia
181 drugs (98 approved, 83 experimental)
Drugs by status
Phase 4 trials (1)
Phase 3 trials (1)
Phase 2 trials (21)
Phase 1 trials (4)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (10)
Organization Involved with Phase 2 Indications (23)
- Genentech
- Genzyme
- Biogen
- GlaxoSmithKline
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- National Center for Research Resources (NCRR)
- National Institute of Neurological Disorders and Stroke (NINDS)
- Baylor University
- Harvard University
- Dartmouth University
- Johns Hopkins University
- Marshall University
- Ohio State University
- University of Rochester
- Mayo Clinic
- Columbia University
- Janssen Pharmaceutica NV
- University of Texas at Houston
- Methodist Cancer Center, Houston, Texas
- Department of Veteran Affairs
- Edwards Foundation, Inc.
- Celularity, Inc.
Organization Involved with Phase 1 Indications (6)
Organization Involved with Other Experimental Indications (1)